- Home
- MOS vs ILMN Comparison
MOS vs ILMN Comparison
Compare MOS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- ILMN
- Stock Information
- Founded
- MOS 1987
- ILMN 1998
- Country
- MOS United States
- ILMN United States
- Employees
- MOS N/A
- ILMN N/A
- Industry
- MOS Agricultural Chemicals
- ILMN Medical Specialities
- Sector
- MOS Industrials
- ILMN Health Care
- Exchange
- MOS Nasdaq
- ILMN Nasdaq
- Market Cap
- MOS 11.2B
- ILMN 13.1B
- IPO Year
- MOS 2004
- ILMN 2000
- Fundamental
- Price
- MOS $36.90
- ILMN $109.30
- Analyst Decision
- MOS Buy
- ILMN Buy
- Analyst Count
- MOS 12
- ILMN 17
- Target Price
- MOS $37.00
- ILMN $124.35
- AVG Volume (30 Days)
- MOS 4.5M
- ILMN 2.3M
- Earning Date
- MOS 08-05-2025
- ILMN 07-31-2025
- Dividend Yield
- MOS 2.38%
- ILMN N/A
- EPS Growth
- MOS N/A
- ILMN N/A
- EPS
- MOS 1.15
- ILMN N/A
- Revenue
- MOS $11,064,300,000.00
- ILMN $4,337,000,000.00
- Revenue This Year
- MOS $17.50
- ILMN N/A
- Revenue Next Year
- MOS N/A
- ILMN $3.15
- P/E Ratio
- MOS $31.96
- ILMN N/A
- Revenue Growth
- MOS N/A
- ILMN N/A
- 52 Week Low
- MOS $22.36
- ILMN $68.70
- 52 Week High
- MOS $38.23
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- MOS 55.68
- ILMN 73.79
- Support Level
- MOS $35.28
- ILMN $92.25
- Resistance Level
- MOS $37.53
- ILMN $99.34
- Average True Range (ATR)
- MOS 0.95
- ILMN 3.61
- MACD
- MOS 0.01
- ILMN 0.66
- Stochastic Oscillator
- MOS 62.22
- ILMN 95.79
About MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.